Which has preferable earnings & valuation, CALC or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is CALC or CTOR more profitable?

Citius Oncology's return on equity of -99.47% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Citius Oncology N/A -99.47% -42.16%

Which has stronger valuation & earnings, CALC or IMMP?

CalciMedica has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A Prima BioMed $6.69M 9.53 -$39.78M N/A N/A

Is CALC or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Prima BioMed N/A N/A N/A

Is CALC or UPXI more profitable?

CalciMedica has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Upexi -874.00% -66.70% -19.56%

Do analysts rate CALC or INCR?

CalciMedica currently has a consensus target price of $10.00, suggesting a potential upside of 1,243.36%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts plainly believe CalciMedica is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CALC or INCR more profitable?

InterCure's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% InterCure N/A N/A N/A

Is CALC or IMA more profitable?

ImageneBio's return on equity of -38.96% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% ImageneBio N/A -38.96% -34.60%

CalciMedica (CALC) Competitors

$0.74 -0.07 (-8.98%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$0.73 -0.01 (-1.67%)

As of 09:10 AM Eastern

Compare

CALC vs. CTOR, IMMP, UPXI, INCR, and IMA

Should you buy CalciMedica stock or one of its competitors? MarketBeat compares CalciMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CalciMedica include Citius Oncology (CTOR), Prima BioMed (IMMP), Upexi (UPXI), InterCure (INCR), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry.

How does CalciMedica compare to Citius Oncology?

CalciMedica (NASDAQ:CALC) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

CalciMedica has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.47, suggesting that its share price is 247% more volatile than the broader market.

Citius Oncology's return on equity of -99.47% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Citius Oncology	N/A	-99.47%	-42.16%

CalciMedica currently has a consensus price target of $10.00, suggesting a potential upside of 1,243.36%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 823.08%. Given CalciMedica's higher probable upside, equities analysts clearly believe CalciMedica is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, CalciMedica had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for CalciMedica and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.87 beat CalciMedica's score of 0.44 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
CalciMedica	Neutral
Citius Oncology	Very Positive

Citius Oncology is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

70.5% of Citius Oncology shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Citius Oncology beats CalciMedica on 9 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Prima BioMed?

CalciMedica (NASDAQ:CALC) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

CalciMedica has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

CalciMedica has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Prima BioMed	$6.69M	9.53	-$39.78M	N/A	N/A

2.3% of Prima BioMed shares are held by institutional investors. 41.6% of CalciMedica shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CalciMedica and CalciMedica both had 2 articles in the media. Prima BioMed's average media sentiment score of 0.94 beat CalciMedica's score of 0.44 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
CalciMedica	Neutral
Prima BioMed	Positive

Prima BioMed's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Prima BioMed	N/A	N/A	N/A

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 1,243.36%. Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,170.79%. Given CalciMedica's higher possible upside, equities analysts clearly believe CalciMedica is more favorable than Prima BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Prima BioMed beats CalciMedica on 6 of the 9 factors compared between the two stocks.

How does CalciMedica compare to Upexi?

CalciMedica (NASDAQ:CALC) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Upexi has higher revenue and earnings than CalciMedica. Upexi is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Upexi	$15.81M	4.17	-$13.68M	-$0.62	N/A

CalciMedica currently has a consensus target price of $10.00, suggesting a potential upside of 1,243.36%. Upexi has a consensus target price of $8.10, suggesting a potential upside of 867.51%. Given CalciMedica's higher possible upside, equities analysts plainly believe CalciMedica is more favorable than Upexi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Upexi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, CalciMedica had 1 more articles in the media than Upexi. MarketBeat recorded 2 mentions for CalciMedica and 1 mentions for Upexi. Upexi's average media sentiment score of 0.93 beat CalciMedica's score of 0.44 indicating that Upexi is being referred to more favorably in the news media.

Company	Overall Sentiment
CalciMedica	Neutral
Upexi	Positive

CalciMedica has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Upexi	-874.00%	-66.70%	-19.56%

5.7% of Upexi shares are held by institutional investors. 41.6% of CalciMedica shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CalciMedica has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Upexi has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market.

Summary

Upexi beats CalciMedica on 9 of the 15 factors compared between the two stocks.

How does CalciMedica compare to InterCure?

CalciMedica (NASDAQ:CALC) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

In the previous week, InterCure had 1 more articles in the media than CalciMedica. MarketBeat recorded 3 mentions for InterCure and 2 mentions for CalciMedica. InterCure's average media sentiment score of 1.45 beat CalciMedica's score of 0.44 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
CalciMedica	Neutral
InterCure	Positive

8.3% of InterCure shares are held by institutional investors. 41.6% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CalciMedica currently has a consensus target price of $10.00, suggesting a potential upside of 1,243.36%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts plainly believe CalciMedica is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
InterCure	N/A	N/A	N/A

InterCure has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
InterCure	$78.47M	0.69	-$10.37M	$0.03	33.00

CalciMedica has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, InterCure has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Summary

InterCure beats CalciMedica on 10 of the 14 factors compared between the two stocks.

How does CalciMedica compare to ImageneBio?

CalciMedica (NASDAQ:CALC) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

CalciMedica has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

75.0% of ImageneBio shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ImageneBio's return on equity of -38.96% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
ImageneBio	N/A	-38.96%	-34.60%

CalciMedica has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
ImageneBio	$800K	80.14	-$45.35M	-$5.79	N/A

CalciMedica presently has a consensus target price of $10.00, suggesting a potential upside of 1,243.36%. ImageneBio has a consensus target price of $26.50, suggesting a potential upside of 340.20%. Given CalciMedica's higher probable upside, research analysts clearly believe CalciMedica is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

In the previous week, CalciMedica had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for CalciMedica and 1 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.70 beat CalciMedica's score of 0.44 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Overall Sentiment
CalciMedica	Neutral
ImageneBio	Positive

Summary

CalciMedica beats ImageneBio on 8 of the 14 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.92M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.57	20.98	26.95	24.38
Price / Sales	N/A	311.10	520.27	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-1.62	8.54	10.81	6.33
Net Income	-$29.56M	$23.83M	$3.59B	$331.02M
7 Day Performance	-17.29%	-2.77%	-1.54%	-0.33%
1 Month Performance	-14.44%	5.85%	2.74%	-1.29%
1 Year Performance	-63.69%	52.15%	28.53%	21.30%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	2.9281 of 5 stars	$0.74 -9.0%	$10.00 +1,243.4%	-67.9%	$12.92M	N/A	N/A	30
CTOR Citius Oncology	2.6884 of 5 stars	$0.70 +8.3%	$6.00 +751.9%	-66.5%	$65.49M	N/A	N/A	N/A	Positive News
IMMP Prima BioMed	2.5687 of 5 stars	$0.43 +3.4%	$5.50 +1,176.4%	-74.4%	$63.50M	$6.69M	N/A	2,021
UPXI Upexi	2.569 of 5 stars	$0.90 +14.1%	$8.10 +804.9%	-86.0%	$62.89M	$15.81M	N/A	130
INCR InterCure	1.3583 of 5 stars	$1.13 +2.7%	N/A	-36.1%	$61.79M	$78.47M	37.67	350	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. CTOR, IMMP, UPXI, INCR, and IMA

How does CalciMedica compare to Citius Oncology?

Summary

How does CalciMedica compare to Prima BioMed?

Summary

How does CalciMedica compare to Upexi?

Summary

How does CalciMedica compare to InterCure?

Summary

How does CalciMedica compare to ImageneBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. CTOR, IMMP, UPXI, INCR, and IMA

How does CalciMedica compare to Citius Oncology?

Which has more volatility and risk, CALC or CTOR?

Is CALC or CTOR more profitable?

Do analysts rate CALC or CTOR?

Does the media favor CALC or CTOR?

Which has preferable earnings & valuation, CALC or CTOR?

Do insiders and institutionals hold more shares of CALC or CTOR?

Summary

How does CalciMedica compare to Prima BioMed?

Which has more volatility and risk, CALC or IMMP?

Which has stronger valuation & earnings, CALC or IMMP?

Do institutionals and insiders believe in CALC or IMMP?

Does the media prefer CALC or IMMP?

Is CALC or IMMP more profitable?

Do analysts recommend CALC or IMMP?

Summary

How does CalciMedica compare to Upexi?

Which has higher earnings & valuation, CALC or UPXI?

Do analysts rate CALC or UPXI?

Does the media prefer CALC or UPXI?

Is CALC or UPXI more profitable?

Do institutionals & insiders hold more shares of CALC or UPXI?

Which has more risk & volatility, CALC or UPXI?

Summary

How does CalciMedica compare to InterCure?

Does the media favor CALC or INCR?

Do insiders and institutionals hold more shares of CALC or INCR?

Do analysts rate CALC or INCR?

Is CALC or INCR more profitable?

Which has stronger earnings and valuation, CALC or INCR?

Which has more volatility and risk, CALC or INCR?

Summary

How does CalciMedica compare to ImageneBio?

Which has more volatility and risk, CALC or IMA?

Do institutionals & insiders hold more shares of CALC or IMA?

Is CALC or IMA more profitable?

Which has higher valuation & earnings, CALC or IMA?

Do analysts rate CALC or IMA?

Does the media prefer CALC or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools